Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma

Ortal Harush, Nathalie Asherie, Shlomit Kfir-Erenfeld, Galit Adler, Tilda Barliya, Miri Assayag, Moshe E. Gatt, Polina Stepensky*, Cyrille J. Cohen*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Chimeric antigen receptor (CAR) T-cell based immunotherapy has become a promising treatment mainly for hematological malignancies. Following the major success of CD19-targeted CAR, new potential targets for other malignancies are required. As such, B-cell maturation antigen (BCMA) is an attractive tumor-associated antigen to be targeted in multiple myeloma (MM). Herein, we aimed at assessing the function and optimal configuration of different BCMA-specific CAR, based on the same targeting moiety but with a different hinge and co-stimulatory domain. We compared their function to that of a previously characterized BCMA-CAR used in clinical trials. All constructs were expressed at high levels by primary human T cells and could trigger cytokine production and cytotoxicity upon co-culture with multiple myeloma targets. Nonetheless, critical differences were observed in off-target activation, exhaustion, and activation marker expression and in vivo antitumoral activity mediated by these different constructs. Interestingly, we noted that CD8-based hinge, combined with a 4-1BB intracellular domain, proved superior compared to IgG4-connecting regions, and/or a CD28-signaling moiety respectively. Overall, this study emphasizes the influence of CAR primary structure on its function and led to the identification of a highly efficient BCMA-specific CAR, namely H8BB, which displayed superior anti-tumoral activity both in vitro and long-term in vivo efficacy.

Original languageAmerican English
Pages (from-to)2395-2407
Number of pages13
Issue number10
StatePublished - 1 Oct 2022

Bibliographical note

Publisher Copyright:
©2022 Ferrata Storti Foundation.


Dive into the research topics of 'Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma'. Together they form a unique fingerprint.

Cite this